J&J to Buy Novira with an Eye on Hep B Cure

Source: Philadelphia Biz Journal

Nov 05, 2015

Johnson & Johnson has agreed to acquire Pennsylvania-based Novira Therapeutics, a biopharmaceutical company working on a potential cure for patients with chronic hepatitis B infection.

Novira, founded in 2009, offers new drug candidate, NVR 3-778, a small-molecule, oral antiviral medicine.

J&J’s Novira buy is the company's second significant hepatitis-related deal in recent months. In May, J&J's Janssen announced a potential $1.1 billion collaboration with Connecticut-based Achillion Pharmaceuticals to to develop and commercialize one or more of Achillion's lead hepatitis C virus assets

The financial terms of the Novira deal were not disclosed. J&J expects the deal to close during the fourth quarter of 2015.

Read the Biz Journal article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments